甲状腺乳头状癌与乳头状增生的病理研究  

Pathological study of papillary thyroid carcinoma and papillary thyroid hyperplasia

作　　者：梁粉花[1] 付青[1] 戴翠华[1] 王刚平[1] 李江涛[1] 赵明春[1] 

机构地区：[1]山东省日照市人民医院病理科,276800

出　　处：《肿瘤研究与临床》2006年第11期755-756,共2页Cancer Research and Clinic

摘　　要：目的探讨Galectin3,CK19及Ki-67在甲状腺乳头状癌与乳头状增生中的表达,寻找有助于两者鉴别诊断的标志物。方法运用免疫组化方法检测100例甲状腺乳头状癌、100例良性乳头状增生中Galectin3,CK19及Ki-67的表达。结果Galectin3,CK19及Ki-67在甲状腺乳头状癌阳性表达率分别为100%,97%及93%,而在乳头状增生中表达率分别为13%,30%及1%,3种蛋白在乳头状癌与良性乳头状增生间差异有统计学意义(P<0.05)。在乳头状癌中2种或3种蛋白同时阳性表达为94.3%,而乳头状增生为0。结论Galectin3,CK19及Ki-67是鉴别诊断甲状腺乳头状癌与乳头状增生的有用标志物,尤其联合使用更有价值。Objective To study the expression of Galectin-3,CK19 and Ki-67 in the papillary thyroid carcinoma and papillary thyroid hyperplasia and to find the differential diagnostic makers. Methods A total of 200 cases, including 100 with papillary thyroid carcinoma and 100 papillary thyroid hyperplasia by Immunohistochemistry. Results The positive rates for Galectin-3,CK19 and Ki-67 in the papillary thyroid carcinoma were 100 %, 97 % and 93 %, which were significantly higher than those in the papillary thyroid hyperplasia （13 %, 31%, 1%） （P 〈 0.05）. The positive rate which two or three of the 3 makers in the papillary thyroid carcinoma were 94.3 %, and the positive rate which two or three of the 3 makers in the papillary thyroid hyperplasia were 0 %. Conclusion Galectin-3, CK19 and Ki-67 were useful makers to distinguish the papillary thyroid carcinoma from papillary thyroid hyperplasia, especially combined application.

关 键 词：Galectin3 CK19 KI-67 甲状腺乳头状癌 甲状腺乳头状增生 

分 类 号：R736.1[医药卫生—肿瘤]